Stocklytics Platform
Asset logo for symbol ELTX
Elicio Therapeutics, Inc. - Common Stock
ELTX45
$4.99arrow_drop_up2.45%$0.12
Penny Stock
Asset logo for symbol ELTX
ELTX45

$4.99

arrow_drop_up2.45%

Performance History

Chart placeholder
Key Stats
Open$5.10
Prev. Close$4.88
EPS-3.44
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$53.53M
PE Ratio-
LOWHIGH
Day Range4.86
4.99
52 Week Range2.96
11.45
Ratios
Revenue-
EBITDA Margin %-
EPS-3.44

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Elicio Therapeutics, Inc. - Common Stock (ELTX)

Elicio Therapeutics, Inc. (ELTX) is a biotechnology company focused on developing highly targeted immunotherapies for the treatment of cancer and other diseases. The company's innovative approach is based on its proprietary Amphiphile technology, which enables the delivery of immunotherapies directly to the lymph nodes, where immune responses are initiated. By targeting the lymphatic system, Elicio's therapies have the potential to generate robust and durable immune responses against tumor cells.
ELTX is committed to revolutionizing cancer treatment by harnessing the power of the immune system. The company's lead product candidate, ELTX-101, is a personalized cancer immunotherapy that combines the patient's own tumor antigens with Elicio's Amphiphile platform. By delivering tumor antigens directly to the lymph nodes, ELTX-101 aims to stimulate a targeted immune response against the patient's specific cancer cells. Preliminary results from a Phase 1/2 clinical trial have shown promising safety and efficacy data, with several patients experiencing tumor shrinkage or stabilization.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert T. Connelly
Headquarters
Boston
Employees
23
Exchange
NASDAQ
add Elicio Therapeutics, Inc. - Common Stock to watchlist

Keep an eye on Elicio Therapeutics, Inc. - Common Stock

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Elicio Therapeutics, Inc. - Common Stock's (ELTX) price per share?

The current price per share for Elicio Therapeutics, Inc. - Common Stock (ELTX) is $5. The stock has seen a price change of $0.12 recently, indicating a 2.46% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Elicio Therapeutics, Inc. - Common Stock (ELTX)?

For Elicio Therapeutics, Inc. - Common Stock (ELTX), the 52-week high is $11.45, which is 129.23% from the current price. The 52-week low is $2.96, the current price is 68.75% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Elicio Therapeutics, Inc. - Common Stock (ELTX) a growth stock?

Elicio Therapeutics, Inc. - Common Stock (ELTX) has shown an average price growth of -5.18% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Elicio Therapeutics, Inc. - Common Stock as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Elicio Therapeutics, Inc. - Common Stock (ELTX) stock price performance year to date (YTD)?

As of the latest data, Elicio Therapeutics, Inc. - Common Stock (ELTX) has a year-to-date price change of -15.77%. Over the past month, the stock has experienced a price change of 1.32%. Over the last three months, the change has been 0.3%. Over the past six months, the figure is -30.04%.
help

Is Elicio Therapeutics, Inc. - Common Stock (ELTX) a profitable company?

Elicio Therapeutics, Inc. - Common Stock (ELTX) has a net income of -$35.2M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$35.74M. Furthermore, the EBITDA is -$41M.
help

What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock (ELTX)?

Elicio Therapeutics, Inc. - Common Stock (ELTX) has a market capitalization of $53.53M. The average daily trading volume is 4.95, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level